{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:36:23Z","timestamp":1782902183703,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ULL Research Group in Food and Environmental Toxicology (Grupo Inter universitario de Toxicolog\u00eda Alimentaria y Ambiental)"},{"name":"Juan Ram\u00f3n Ayala Santana Community Pharmacy Company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Users of benzodiazepines (BZDs) should have their quality of life monitored to minimize the risks associated with long-term treatments. The aim of this study is to use the EuroQol 5D-3L to analyze the quality of life of 127 patients under treatment with BZDs during the COVID-19 pandemic. The results show that lorazepam comprises 25.49% of all dispensing requests, and that the mean duration of BZDs treatments is four years (range: 0.3\u201325). When rating their general health status, BZDs users reported 59.29 points out of 100. Thirty-two percent of patients reported mobility problems; 16.5% reported having a lot of pain or discomfort despite being treated with BZDs, and 16.54% used a BZD together with an opioid analgesic. The EuroQol 5D-3L dimension \u201canxiety\/depression\u201d showed that, despite the use of BZDs, 48.2% of the patients reported being moderately anxious or depressed and 13.4% described themselves as very anxious or depressed. Nevertheless, 37.8% of BZDs users were identified as potential candidates to follow a BZD deprescription plan. In conclusion, BZDs users showed a low quality of life during the COVID-19 pandemic. Older patients and females have been identified as groups of patients that could benefit from integrating the use of the EuroQol 5D-3L instrument into the protocols of the pharmaceutical care follow up.<\/jats:p>","DOI":"10.3390\/pharmacy11010019","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T02:51:37Z","timestamp":1674096697000},"page":"19","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quality of Life Assessment in Patients Using Benzodiazepines during the COVID-19 Pandemic in a Community Pharmacy Using EuroQol 5D-3L"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-7405","authenticated-orcid":false,"given":"Daida","family":"Alberto Armas","sequence":"first","affiliation":[{"name":"Toxicology Department, Universidad de La Laguna, 38071 Canary Islands, Spain"},{"name":"Community Pharmacy, 38010 Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ram\u00f3n","family":"Santana Ayala","sequence":"additional","affiliation":[{"name":"Toxicology Department, Universidad de La Laguna, 38071 Canary Islands, Spain"},{"name":"Community Pharmacy, 38010 Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanira","family":"Rom\u00e1n Castillo","sequence":"additional","affiliation":[{"name":"Nuestra Se\u00f1ora de la Candelaria Hospital, 38010 Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Hardisson de la Torre","sequence":"additional","affiliation":[{"name":"Toxicology Department, Universidad de La Laguna, 38071 Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-5870","authenticated-orcid":false,"given":"Carmen","family":"Rubio Armend\u00e1riz","sequence":"additional","affiliation":[{"name":"Toxicology Department, Universidad de La Laguna, 38071 Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"ref_1","unstructured":"Observatorio de uso de medicamentos. Informe de utilizaci\u00f3n de medicamentos. Utilizaci\u00f3n de medicamentos ansiol\u00edticos e hipn\u00f3ticos en Espa\u00f1a durante el periodo 2010\u20132021 Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Available online: https:\/\/www.aemps.gob.es\/medicamentos-de-uso-humano\/observatorio-de-uso-de-medicamentos\/informes-ansioliticos-hipnoticos\/."},{"key":"ref_2","unstructured":"Observatorio Espa\u00f1ol de las Drogas y las Adicciones. Encuesta sobre alcohol y otras drogas en Espa\u00f1a, EDADES 2021. Madrid: Ministerio de Sanidad. Delegaci\u00f3n del Gobierno para el Plan Nacional sobre Drogas. Available online: https:\/\/pnsd.sanidad.gob.es\/profesionales\/sistemasInformacion\/sistemaInformacion\/pdf\/2019-20_Informe_EDADES.pdf."},{"key":"ref_3","first-page":"379","article-title":"Utilizaci\u00f3n de ansiol\u00edticos e hipn\u00f3ticos en Espa\u00f1a (1995\u20132002)","volume":"78","author":"Madurga","year":"2004","journal-title":"Rev. Espa\u00f1ola De Salud P\u00fablica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4321\/S1135-57272013000300004","article-title":"Evoluci\u00f3n del uso de medicamentos ansiol\u00edticos e hipn\u00f3ticos en Espa\u00f1a durante el per\u00edodo 2000\u20132011","volume":"87","year":"2013","journal-title":"Rev. Espa\u00f1ola De Salud P\u00fablica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.gaceta.2014.02.005","article-title":"Crisis econ\u00f3mica y salud mental. Informe SESPAS 2014","volume":"28","author":"Gili","year":"2014","journal-title":"Gac. Sanit."},{"key":"ref_6","unstructured":"Fl\u00f3rez, J. (2014). F\u00e1rmacos Ansiol\u00edticos Y Sedantes. Farmacolog\u00eda de Los Trastornos Del Sue\u00f1o, Elsevier Masson. Farmacolog\u00eda humana., 6aed."},{"key":"ref_7","first-page":"373","article-title":"Farmacolog\u00eda B\u00e1sica y Cl\u00ednica","volume":"14","author":"Bertram","year":"2019","journal-title":"Ed. McGraw Hill. Madrid."},{"key":"ref_8","first-page":"21","article-title":"An\u00e1lisis de consumo de ansiol\u00edticos e hipn\u00f3ticos en un centro de atenci\u00f3n primaria","volume":"1","year":"2019","journal-title":"Med. Fam. Andal."},{"key":"ref_9","unstructured":"(2017). Encuesta Nacional de Salud ENSE, Espa\u00f1a 2017, SG Informaci\u00f3n Sanitaria Ministerio de Sanidad, Consumo y Bienestar Social."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11606-016-3740-0","article-title":"Benzodiazepines are Prescribed More Frequently to Patients Already at Risk for Benzodiazepine-Related Adverse Events in Primary Care","volume":"31","author":"Kroll","year":"2016","journal-title":"J. Gen. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"g1996","DOI":"10.1136\/bmj.g1996","article-title":"Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: Retrospective cohort study","volume":"348","author":"Weich","year":"2014","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.aprim.2011.07.018","article-title":"Adecuaci\u00f3n de la utilizaci\u00f3n de benzodiacepinas en ancianos desde la oficina de farmacia. Un estudio de colaboraci\u00f3n m\u00e9dico- farmac\u00e9utico","volume":"44","year":"2012","journal-title":"Atenci\u00f3n Primaria"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e022046","DOI":"10.1136\/bmjopen-2018-022046","article-title":"Intervention to reduce benzodiazepine prescriptions in primary care, study protocol of a hybrid type 1 cluster randomised controlled trial: The BENZORED study","volume":"9","author":"Vicens","year":"2019","journal-title":"BMJ Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamainternmed.2014.949","article-title":"Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: The EMPOWER cluster randomized trial","volume":"174","author":"Tannenbaum","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_15","first-page":"188","article-title":"BENZOSTOPJUNTOS 2: Efectividad de una intervenci\u00f3n comunitaria en el uso cr\u00f3nico de benzodiazepinas: Estudio aleatorizado controlado","volume":"12","author":"Atienza","year":"2020","journal-title":"Farm. Comunitarios"},{"key":"ref_16","first-page":"83","article-title":"BENZOSTOPJUNTOS-1: Efectividad al a\u00f1o de una intervenci\u00f3n comunitaria en el uso cr\u00f3nico de benzodiazepinas. Calidad de vida y variables no diferenciadoras en el abandono","volume":"12","author":"Ferrer","year":"2020","journal-title":"Farm. Comunitarios"},{"key":"ref_17","first-page":"637","article-title":"El papel de la depresi\u00f3n, la ansiedad, el estr\u00e9s y la adhesi\u00f3n al tratamiento en la calidad de vida relacionada con la salud en pacientes en di\u00e1lisis: Revisi\u00f3n sistem\u00e1tica de la literatura","volume":"34","author":"Remor","year":"2014","journal-title":"Nefrologia"},{"key":"ref_18","first-page":"508","article-title":"Health-related quality of life in caregivers of patients with Alz- heimer disease","volume":"32","year":"2017","journal-title":"Neurolog\u00eda"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1590\/1413-81232020252.16382017","article-title":"Calidad de vida relacionada con la salud: Exclusi\u00f3n de la subjetividad","volume":"25","year":"2020","journal-title":"Ci\u00eanc. Sa\u00fade Coletiva"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jval.2014.02.002","article-title":"The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups","volume":"17","author":"Little","year":"2014","journal-title":"Value Health"},{"key":"ref_21","unstructured":"(2022, December 01). EuroQol Research Foundation. [Internet]EQ-5D-3L User Guide. Available online: https:\/\/euroqol.org\/publications\/user-guides."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102041","DOI":"10.1016\/j.aprim.2021.102041","article-title":"Calidad de vida relacionada con la salud en pacientes consumidores de benzodiacepinas","volume":"53","author":"Moreno","year":"2021","journal-title":"Atenci\u00f3n Primaria"},{"key":"ref_23","first-page":"23","article-title":"G\u00e9nero y uso de medicamentos ansiol\u00edticos e hipn\u00f3ticos en Espa\u00f1a","volume":"5","year":"2017","journal-title":"J. Fem. Gend. Women Stud."},{"key":"ref_24","first-page":"255","article-title":"Dispensaci\u00f3n de benzodiacepinas y an\u00e1logos en farmacias comunitarias de Valladolid","volume":"15","year":"2013","journal-title":"Pharm. Care Esp."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.gaceta.2019.06.012","article-title":"Benzocarta: Intervenci\u00f3n m\u00ednima para la desprescripci\u00f3n de benzodiacepinas en pacientes con insomnio","volume":"34","author":"Uria","year":"2020","journal-title":"Gac. Sanit."},{"key":"ref_26","first-page":"93","article-title":"BENZOSTOPJUNTOS-1: Opiniones y actitudes de los pacientes con benzodiacepinas y predictores del abandono tras recibir una intervenci\u00f3n comunitaria","volume":"12","author":"Ferrer","year":"2020","journal-title":"Farm. Comunitarios"},{"key":"ref_27","first-page":"1","article-title":"Trastornos psiqui\u00e1tricos en la edad media de la vida","volume":"166","year":"2004","journal-title":"Una Epidemia Silenciosa"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1002\/hsr2.116","article-title":"Benzodiazepine usage and patient preference for alternative therapies: A descriptive study","volume":"2","author":"Sake","year":"2019","journal-title":"Health Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.gaceta.2015.08.007","article-title":"El EQ-5D como medida de resultados en salud","volume":"29","year":"2015","journal-title":"Gac. Sanit."},{"key":"ref_30","unstructured":"Gastelurrutia, M.A., Fern\u00e1ndez-Rodr\u00edguez, M., Garc\u00eda-C\u00e1rdenas, V., Meg\u00eda Arias, C., P\u00e9rez-Escamilla, B., Varas-Doval, R., Zarzuelo Romero, M., and Mart\u00ednez-Maart\u00ednez, F. (2018). conSIGUE: Generalizaci\u00f3n de la Implantaci\u00f3n Del Servicio de Seguimiento Farmacoterap\u00e9utico, CGCOF."},{"key":"ref_31","unstructured":"Mart\u00ednez-Mart\u00ednez, F., Garc\u00eda, M.V., Gastelurrutia, M.A., Varas, R., Peir\u00f3, T., and S\u00e1ez-Benito, L. (2019). Informe Global 2019 AdherenciaMED: Dise\u00f1o, Evaluaci\u00f3n Del Impacto E Implantaci\u00f3n de Un Servicio Profesional de Adherencia Terap\u00e9utica Desde El \u00e1Mbito de la Farmacia Comunitaria, CGCOF."},{"key":"ref_32","first-page":"91","article-title":"An\u00e1lisis de la comorbilidad y calidad de vida de pacientes mayores polimedicados","volume":"9","year":"2016","journal-title":"Rev. Cl\u00edn. Med. Fam."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/11\/1\/19\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:09:18Z","timestamp":1760119758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/11\/1\/19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["pharmacy11010019"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy11010019","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]}}}